Page last updated: 2024-10-18

iodine and Cough

iodine has been researched along with Cough in 13 studies

Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

ExcerptRelevanceReference
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)."7.73Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005)
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus."7.65Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975)
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)."3.73Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005)
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus."3.65Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975)
" Common adverse events in part B included cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%])."2.82Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. ( Cooke, J; Cunningham, S; Davies, JC; Green, Y; Harris, WT; Lapey, A; Regelmann, WE; Robertson, S; Rosenfeld, M; Sawicki, GS; Southern, KW, 2016)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19906 (46.15)18.7374
1990's1 (7.69)18.2507
2000's2 (15.38)29.6817
2010's2 (15.38)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Rosiles, R1
Buck, WB1
Brown, LN1
Morgan, EJ1
Petty, TL1
Calamai, G1
Perna, AM1
Venturini, A1
Block, SH1
Kim, M1
Zang, DY1
Lee, J1
Park, JY1
Chung, Y1
Lee, YK1
Berens, DP1
Huh, HS1
Mazur, LJ1
Davies, JC1
Cunningham, S1
Harris, WT1
Lapey, A1
Regelmann, WE1
Sawicki, GS1
Southern, KW1
Robertson, S1
Green, Y1
Cooke, J1
Rosenfeld, M1
Claassens, MM1
van Schalkwyk, C1
Floyd, S1
Ayles, H1
Beyers, N1
Lukela, M1
DeGuzman, D1
Weinberger, S1
Saint, S1
Ahn, KM1
Park, HY1
Lee, JH1
Lee, MG1
Kim, JH1
Kang, IJ1
Lee, SI1
Wood, RE1
McCombs, ML1
Shwachman, H1
Redmond, A1
Khaw, KT1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation[NCT01705145]Phase 335 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI = (Weight [in kg]) divided by (Stature [in meters])^2. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Baseline, Week 24

Interventionkilogram per square meter (kg/m^2) (Mean)
Part B: Ivacaftor 50 mg0.332
Part B: Ivacaftor 75 mg0.314
Part B: Overall Ivacaftor0.319

Part B: Absolute Change From Baseline in Stature at Week 24

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventioncentimeters (cm) (Mean)
Part B: Ivacaftor 50 mg2.5
Part B: Ivacaftor 75 mg3.5
Part B: Overall Ivacaftor3.3

Part B: Absolute Change From Baseline in Sweat Chloride at Week 24

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionmillimole per liter (mmol/L) (Mean)
Part B: Ivacaftor 50 mg-47.07
Part B: Ivacaftor 75 mg-46.78
Part B: Overall Ivacaftor-46.86

Part B: Absolute Change From Baseline in Weight at Week 24

Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionkilograms (kg) (Mean)
Part B: Ivacaftor 50 mg1.00
Part B: Ivacaftor 75 mg1.50
Part B: Overall Ivacaftor1.36

Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants." (NCT01705145)
Timeframe: Part A: Up to 93 Days

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part A: Ivacaftor 50 mg301
Part A: Ivacaftor 75 mg503
Part A: Overall Ivacaftor804

Part A: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor [M1] and ivacaftor carboxylate [M6]) up to 24 hours post-dose on Day 4 (Hour 0 [pre-dose] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part A: up to 24 hours post-dose on Day 4

Interventionnanogram per milliliter (ng/mL) (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 4Ivacaftor: 2 Hours Post-Dose on Day 4Ivacaftor: 3 Hours Post-Dose on Day 4Ivacaftor: 6 Hours Post-Dose on Day 4Ivacaftor: 24 Hours Post-Dose on Day 4M1: Hour 0 on Day 1M1: Hour 0 on Day 4M1: 2 Hours Post-Dose on Day 4M1: 3 Hours Post-Dose on Day 4M1: 6 Hours Post-Dose on Day 4M1: 24 Hours Post-Dose on Day 4M6: Hour 0 on Day 1M6: Hour 0 on Day 4M6: 2 Hours Post-Dose on Day 4M6: 3 Hours Post-Dose on Day 4M6: 6 Hours Post-Dose on Day 4M6: 24 Hours Post-Dose on Day 4
Part A: Overall Ivacaftor0.003967269575421240.0012401540231015803890.001150105013001390439

Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received." (NCT01705145)
Timeframe: Part B: Up to 28 Weeks

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part B: Ivacaftor 50 mg1033
Part B: Ivacaftor 75 mg2338
Part B: Overall Ivacaftor33611

Part B: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 [predose] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part B: up to 24 hours post-dose on Day 168

Interventionng/mL (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 14Ivacaftor: 2 Hours Post-Dose on Day 14Ivacaftor: 3 Hours Post-Dose on Day 14Ivacaftor: 6 Hours Post-Dose on Day 14Ivacaftor: Hour 0 on Day 56Ivacaftor: 1 Hour Post-Dose on Day 56Ivacaftor: Hour 0 on Day 112Ivacaftor: 4 Hours Post-Dose on Day 112Ivacaftor: 6 Hours Post-Dose on Day 112Ivacaftor: Hour 0 on Day 168Ivacaftor: 24 Hours Post-Dose on Day 168M1: Hour 0 on Day 1M1: Hour 0 on Day 14M1: 2 Hours Post-Dose on Day 14M1: 3 Hours Post-Dose on Day 14M1: 6 Hours Post-Dose on Day 14M1: Hour 0 on Day 56M1: 1 Hour Post-Dose on Day 56M1: Hour 0 on Day 112M1: 4 Hours Post-Dose on Day 112M1: 6 Hours Post-Dose on Day 112M1: Hour 0 on Day 168M1: 24 Hours Post-Dose on Day 168M6: Hour 0 on Day 1M6: Hour 0 on Day 14M6: 2 Hours Post-Dose on Day 14M6: 3 Hours Post-Dose on Day 14M6: 6 Hours Post-Dose on Day 14M6: Hour 0 on Day 56M6: 1 Hour Post-Dose on Day 56M6: Hour 0 on Day 112M6: 4 Hours Post-Dose on Day 112M6: 6 Hours Post-Dose on Day 112M6: Hour 0 on Day 168M6: 24 Hours Post-Dose on Day 168
Part B: Overall Ivacaftor0.0061493210801140448514596108010105002070.0015801870228026701340117016802450250014606020.001520143016302090151013101660181021301520632

Reviews

3 reviews available for iodine and Cough

ArticleYear
Hydatid disease of the heart. Report of five cases and review of the literature.
    Thorax, 1974, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Cardiomegaly; Child; Cough; Diagnosis, Differential; Echinococcosis; Edema; Elect

1974
Cystic fibrosis: diagnosis, treatment, and prognosis.
    Southern medical journal, 1979, Volume: 72, Issue:2

    Topics: Aerosols; Anti-Bacterial Agents; Cough; Cystic Fibrosis; Diet; Female; Humans; Infant, Newborn; Infa

1979
Research in cystic fibrosis: a review.
    Texas reports on biology and medicine, 1973,Winter, Volume: 31, Issue:4

    Topics: Biological Transport; Calcium; Cells, Cultured; Child; Chlorides; Cough; Cystic Fibrosis; Digestive

1973

Trials

2 trials available for iodine and Cough

ArticleYear
Summary of the National Mucolytic Study.
    Chest, 1990, Volume: 97, Issue:2 Suppl

    Topics: Aged; Bronchitis; Chest Pain; Consumer Behavior; Cough; Double-Blind Method; Expectorants; Female; G

1990
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:2

    Topics: Aminophenols; Child, Preschool; Chloride Channel Agonists; Chlorides; Cough; Cystic Fibrosis; Cystic

2016

Other Studies

8 other studies available for iodine and Cough

ArticleYear
Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea.
    American journal of veterinary research, 1975, Volume: 36, Issue:10

    Topics: Ammonia; Animals; Cattle; Cattle Diseases; Cough; Female; Fibrinogen; Infectious Bovine Rhinotrachei

1975
Goiter complicating therapy with iodinated glycerol (Organidin).
    The Journal of pediatrics, 1973, Volume: 83, Issue:1

    Topics: Adolescent; Cough; Expectorants; Female; Follow-Up Studies; Glycerol; Goiter; Humans; Iodine; Thyroi

1973
Mixed Phenotype Acute Leukemia that Evolved from Myelodysplastic Syndrome with Excess Blasts.
    Laboratory medicine, 2020, May-06, Volume: 51, Issue:3

    Topics: Aged; B-Lymphocytes; Basophils; Carcinogenesis; Cough; Dyspnea; Female; Humans; Korea; Leukemia, Bip

2020
Weight Loss, Fever, Cough, and Night Sweats in an 11-year-old Girl.
    Pediatrics in review, 2020, Volume: 41, Issue:Suppl 1

    Topics: Child; Cough; Diagnosis, Differential; Female; Fever; Humans; Sweat; Weight Loss

2020
Symptom screening rules to identify active pulmonary tuberculosis: Findings from the Zambian South African Tuberculosis and HIV/AIDS Reduction (ZAMSTAR) trial prevalence surveys.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Black People; Communicable Diseases; Cough; Dyspnea; Female; Fever; HIV Infections; Humans; Male; Ma

2017
Clinical problem-solving. Unfashionably late.
    The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1

    Topics: Adolescent; Biopsy; Burkholderia cepacia; Burkholderia Infections; Chest Pain; Chlorides; Cough; Cys

2005
Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis.
    Journal of Korean medical science, 2005, Volume: 20, Issue:1

    Topics: Blood Pressure; Bronchiectasis; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduct

2005
Studies in cystic fibrosis. Report of 130 patients diagnosed under 3 months of age over a 20-year period.
    Pediatrics, 1970, Volume: 46, Issue:3

    Topics: Anemia; Body Weight; Chloramphenicol; Chlortetracycline; Cough; Cystic Fibrosis; Diabetes Mellitus,

1970